Holen Sie sich die Stockscreener-App
2.12
0.15%
-0.010
Schlusskurs vom Vortag:
$2.13
Offen:
$2.13
24-Stunden-Volumen:
33,646
Relative Volume:
0.02
Marktkapitalisierung:
$28.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.16M
KGV:
-6.2353
EPS:
-0.34
Netto-Cashflow:
$-39.49M
1W Leistung:
+5.29%
1M Leistung:
-11.38%
6M Leistung:
-30.27%
1J Leistung:
-38.35%
1-Tages-Spanne:
$2.10
$2.16
1-Wochen-Bereich:
$2.02
$2.1931
52-Wochen-Spanne:
$1.83
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Firmenname
Dare Bioscience Inc
Sektor
Branche
Telefon
858-926-7655
Adresse
3655 NOBEL DRIVE, SAN DIEGO, CA
Vergleichen Sie DARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.1004 | 28.71M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.70 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.34 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.40 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
747.52 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.43 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
Maxim upgrades Daré Bioscience on extended cash runway, commercial launch - TradingView
Maxim Group upgrades Dare Bioscience stock to Buy on funding boost - Investing.com
Dare Bioscience shares rise 4.37% premarket after Maxim upgraded to Buy from Hold. - AInvest
Dare Bioscience: Maxim Group upgrades Buy from Hold, PT $8. - AInvest
Maxim Upgrades Dare Bioscience to Buy From Hold, Price Target is $8 - MarketScreener
Daré Bioscience Engages Market with New Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Pattern recognition hints at Daré Bioscience Inc. upsideQuarterly Trade Review & Long-Term Safe Investment Ideas - Newser
Brookline Capital Markets Sticks to Their Buy Rating for Daré Bioscience (DARE) - The Globe and Mail
Dolliver Maintains Buy Rating on Daré Bioscience with $11 Price Target - AInvest
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates - MSN
Dare Bioscience stock price target lowered to $11 at Brookline Capital - Investing.com Canada
Daré Bioscience's Strategic Growth and Market Expansion Ahead of Sildenafil Cream Launch - AInvest
Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch - TipRanks
Dare Bioscience risks Nasdaq delisting over market value - MSN
Dare Bioscience shares fall 3.55% after-hours following Q2 2025 earnings call. - AInvest
Dare Bioscience 2025 Q2 Earnings Net Loss Widens Sharply - AInvest
Dare Bioscience 2025 Q2 Earnings Sharp Net Loss Deteriorates 131% - AInvest
Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy - MSN
Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Daré Bioscience Announces Q2 2025 Financial Results - TipRanks
Daré Bioscience Q2 2025 Earnings Call: Financial Results and Business Update - AInvest
Daré Bioscience's Q2 2025: Diverging Paths in Marketing, Financial Health, and R&D Investment - AInvest
Daré Bioscience's Q2 2025 Earnings: A Strategic Inflection Point in Women's Health Innovation - AInvest
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings call transcript: Dare Bioscience Q2 2025 reports cash boost, product updates - Investing.com Canada
Transcript : Daré Bioscience, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
Daré Bioscience Readies First Commercial Product Launch as Multiple Women's Health Solutions Near Market - Stock Titan
Dare Bioscience Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Dare Bioscience (DARE) down more than 70% since Jul 14 - AInvest
Daré Bioscience to Host Second Quarter 2025 Financial - GlobeNewswire
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - The Manila Times
Daré Bioscience to Present Q2 Results: Women's Health Pipeline and Financial Updates Coming August 14 - Stock Titan
Dare Bioscience shares fall 1.61% premarket after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Dare Bioscience shares fall 2.75% intraday after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Daré Bioscience and Rosy Wellness Launch First Phase of - GlobeNewswire
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - The Manila Times
Revolutionary Female Viagra Cream DARE to PLAY Gets Major Launch Campaign Before Q4 Release - Stock Titan
Daré Bioscience Meets Nasdaq Equity Requirement - TipRanks
Daré Bioscience Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - Autocar Professional
UPDATEDaré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - The Manila Times
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - GlobeNewswire
Revolutionary Female Viagra Cream: First-Ever FDA-Approved Sildenafil Treatment for Women Coming This Year - Stock Titan
Daré Bioscience Unveils First Topical Sildenafil Cream for Women's Arousal, Set for Prescription Launch in Q4 2025 - Quiver Quantitative
Daré Bioscience Reports Positive Contraception Trial Results as Smart Drug Delivery Platform Shows Broader Potential - Femtech Insider
Finanzdaten der Dare Bioscience Inc-Aktie (DARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):